Defunct Company
Total Trials
12
As Lead Sponsor
10
As Collaborator
2
Total Enrollment
552
NCT00993239
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 30, 2009
Completion: Mar 31, 2013
NCT01188499
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
Phase: Phase 1/2
Start: Oct 31, 2010
Completion: Mar 31, 2014
NCT01433731
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
Start: Nov 30, 2011
Completion: Sep 30, 2013
NCT01573780
Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
Role: Collaborator
Start: Apr 30, 2012
Completion: Not specified
NCT01646567
SHP-141C in Plaque Type Psoriasis
Start: Sep 30, 2012
Completion: Nov 30, 2012
NCT01828346
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
Start: Jun 30, 2013
Completion: Nov 30, 2015
NCT01940172
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
Start: Nov 30, 2013
Completion: Dec 31, 2015
NCT02147873
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
Phase: Phase 2
Start: Jun 30, 2014
Completion: Jun 30, 2016
NCT02213861
Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma
Start: Nov 30, 2014
Completion: Oct 31, 2016
NCT02288208
Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B
Completion: May 31, 2015
NCT02636244
Safety and Efficacy Study of SHAPE Gel in Alopecia Areata
Start: Feb 28, 2017
Completion: Jan 31, 2018
NCT02756130
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Start: Aug 1, 2018
Completion: Feb 1, 2021